HALBERD CORPORATION holds the exclusive rights to the COVID-19 extracorporeal treatment technology
(based on granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287 and 7 provional COVID-19 patents)
HALB Security Details - https://www.otcmarkets.com/stock/HALB/security
Authorized Shares - 800,000,000 - a/o 04/09/2021
Shares Outstanding - 439,621,968 - a/o 04/09/2021
Float- 394,328,243 - a/o 04/09/2021
Halberd Corp. (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements.
It is debt-free and holds the exclusive rights to eight COVID-19 extracorporeal treatment technology provisional patent applications:
"Method for Treating and Curing Covid-19 Infection" (International Patent Cooperation Treaty, 150 countries, pending)
"Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients"
"Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus"
"Method For The Rapid Identification Of Covid-19 Infection
"Nasal spray to Prevent the Transmission of COVID-19 between Humans"
"Nasal Spray to Prevent the Transmission of Covid-19"
"Method For Treating And Curing Covid-19 Infection By Utilizing Radio Frequency Extracorporeally To Eradicate The Virus"
"Medication For The Reduction Of Morbidity And Mortality In Persons Infected By Sars-Cov-2"
HALB also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287
Halberd Corp has a joint venture on Covid-19 treatment that starts with Dr. Mitchell Felder’s patented extracorporeal therapy (US Patent 9,216,386 and US Patent 8,758,287) for the safe removal of targeted antigens from the blood and targeted organs. Dr. Felder explained, “The extracorporeal treatment is based on the process of removing the underlying basis of the disease. In the case of Covid-19, it entails removal of specific compounds which allow the virus to replicate. We believe this technology is superior to known treatments in that it may potentially eliminate mutations of the virus.” Dr. Felder continued, “With our partners, including a leading university partner, we are now positioned to develop potential cures and mitigation for Covid-19 as well as to alleviate the global drug epidemic for our country and the world. The joint venture includes financial commitments for funding, which if obtained, along with the continued research with our university partner is likely to develop the technology disclosed in our provisional patent application entitled ‘Method for Treating and Curing COVID-19 Infection’. We seek to further develop and establish proof of concept with regard to these promising tools in this worldwide battle. This positions us to facilitate defenses against the growing COVID-19 menace as well as against other viral attacks.”
See YouTube video, https://youtu.be/BGdZqHH6oew, concerning Dr. Felder’s discussion of the scientific basis underlying Premier’s extracorporeal treatment process for fighting cancer and other diseases.
In plain English: HALB with its partners is developing an extra-corporeal (out of the body) treatment against COVID-19
and other virusses and diseases. With the use of antibodies the coronavirus disease antigens is targeted. With radiofrequency
technology antigens and cytokines are eradicated. All based on 2 granted patents and 8 provisional patents.
Halberd Corp. Selects Arizona State University (ASU) to Develop Its Patented COVID-19 Treatment(s)
On May 12th 2020 MARV Enterprises LLC (owned by Dr M. Felder), Premier Biomedical Inc and Halberd Corp (THI) signed an Intellectual Property Agreement (exhibit 10.2), transfering the exclusive rights to the 2 above mentioned granted US Patents and the mentioned 8 provisional Patents exclusively to Halberd Corp:
Trademarkia Trademark (11/07/2020) FELDER-HALBERD MONOCLONAL ANTIBODY Trademark Information:
* Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing;
* Dietary and nutritional supplements containing monoclonal antibody for use in immune system support;
* Pharmaceutical preparations for the treatment and prevention of Covid-19;
* Pharmaceutical preparations for the treatment of immune system related diseases and disorders
The FELDER-HALBERD-ASU monoclonal antibody will be the basis for:
- a rapid Covid-19 diagnostic test
- a Covid-19 preventative nasal spray as an alternative for a vaccine
- a Covid-19 extracorporeal treatment
- a corporeal treatment for other diseases like PTSD, MS, Alzheimer etc (bloodborne or in spinal fluid)
Maintained by Slingwing1
The claim the VA is working with this scam is a totally false and blatent lie! The VA Does not work with shell companies that have no assets.
Datatecnics Corp is a privately held company so what would they have anything to do with a scam like Halberd?
Halberd holds no patents as they are held by Marv Enterprises
It is all a scam. Richard Goulding needs 1.8 Million to pay the fine from the SEC. This has always been a scam shell to bilk money out of investors.
This is the new company headquarters at 1174 East Kingston Square, Lake Charles, Louisiana 70611
Nothing like having a company headquartered out of a DOUBLE WIDE on a foundation with a trashy yard.
This scam is committing fraud as they are advertising Halberd as having 800 Million shares when Halberd Corp no longer exists. All the stock and ticker was transferred to Halberd Transition Corporation under Alaric Corporation on 05-14-2020 with 2 Billion common shares. Read the CO SoS filing carefully.
What does a business selling scam, a drone scam, a beer tap scam, a pot scam and a virus scam have in common? None have so far created a successful business but they have ripped off many investors of their money and Halberd is the culprit.
Be very cautious if trading this scam. The ticker was transfered to Alaric Corp and renamed Halbered Transition Corp back on 03-27-2020. What you think you are trading has no trading symbol. This is a scam. Read the filings at CO SOS.
Maintained by Slingwing1